Stephen Wright breaks down the lengthy process of getting a psychedelic medicine approved in the US.
Once enacted, the proposal will give any adult in the state, aged 21 and over, the legal right to possess, use, cultivate and share psilocybin, ibogaine, mescaline (not derived from peyote), DMT, and psilocyn without fear of arrest.
A new study has found that a single microdose of LSD can increase brain activity related to its reward system.
The largest study to date testing the ability of the psychedelic compound psilocybin to treat a psychiatric disorder has shown that the mushroom-derived drug, delivered in combination with integrative psychotherapy sessions, significantly reduced participants’ depression as compared to a placebo after three weeks.
Scientists have developed a new compound which interacts with the same therapeutic targets in the brain as psychedelic drugs, producing the same long-lasting antidepressant and antianxiety effects but without the psychedelic high.